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Abstract 
The discovery that many inherited diseases are linked to interacting nuclear envelope 
proteins has raised the possibility that human genetics studies could be assisted by a 
fusion with proteomics. Two principles could be applied. In the first, an organelle 
associated with a genetically variable disease is analyzed by proteomics to determine 
its protein complement. The chromosomal locations of the genes encoding these 
proteins are then determined. If a related disease is linked to a large chromosomal 
region that includes a gene identified in the organelle, then that gene has an increased 
likelihood of causing the disease. Directly sequencing this allele from patient samples 
might speed identification compared to further genetic linkage studies, as has been 
demonstrated for multiple diseases associated with the nuclear envelope. The second 
principle is that if an organelle has been implicated in the pathology of a particular 
disorder, then comparison of the organelle proteome from control and patient cells 
might highlight differences that could indicate the causative protein. The distinct, 
tissue-specific pathologies associated with nuclear envelope diseases suggests that 
many tissues will have a set of disorders linked to this organelle, and there are 
numerous as-yet unmapped or partially mapped syndromes that could benefit from 
such an approach. 
 
Introduction 
In the last 10 years, it has become clear that mutations in a small group of nuclear 
envelope (NE) proteins are responsible for at least 15 inherited human diseases (table 
1). The diverse range of tissue-specific clinical phenotypes associated with these 
disorders, and the fact that many of the proteins in question are widely expressed has 
led to a renewed interest in the organization and function of the NE. 
The NE (figure 1) is a double membrane structure consisting of two lipid bilayers 
separated by a regular spacing of around 50 nm. The outer nuclear membrane (ONM) 
is continuous with the endoplasmic reticulum (ER) and its cytoplasmic face is 
similarly studded by ribosomes (1,2). To what extent it resembles more distal ER is 
unclear, but the ONM harbors some distinctive proteins of its own that are involved in 
tethering the NE to the cytoskeleton (3,4). The space between the outer and inner 
membranes forms the lumen, a soluble compartment that is also continuous with the 
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ER. The outer and inner membranes are linked at nuclear pores – large multiprotein 
complexes that span the entire NE, forming gated channels through which all 
transport in and out of the nucleus occurs (5). The inner nuclear membrane (INM) 
hosts a unique complement of integral proteins that interact with chromatin and 
provide attachment points for the nuclear lamina, a fibrous network composed 
principally of the intermediate filament lamin proteins (6,7). Though lamins also 
occur in the nucleoplasm, the vast majority are assembled into the lamina, which is 
closely associated with the INM and is thought to provide strength and support to the 
NE (8-10).  
 
The Nuclear Envelope and Muscular Dystrophy 
In 1994, positional cloning studies identified a gene encoding a novel transmembrane 
protein dubbed emerin that was responsible for X-linked Emery-Dreifuss muscular 
dystrophy (11). Emerin was subsequently localized to the INM (12,13), an 
unexpected finding as emerin is ubiquitously expressed: how could mutations in a 
universal integral NE protein cause a disease predominantly affecting skeletal and 
cardiac muscle and tendons? A further surprise came when mutations in LMNA (an 
alternatively spliced gene which produces lamin A, lamin C, and other variants) were 
shown to cause not only autosomal variants of Emery-Dreifuss muscular dystrophy 
(14,15), but two additional inherited disorders affecting other muscle groups – type 
1B limb-girdle muscular dystrophy (16) and familial dilated cardiac myopathy with 
conduction defects (17). It was subsequently found that emerin and lamin A/C interact 
strongly and that some LMNA mutations lead to the loss of emerin from the NE 
(18,19), providing an explanation for why emerin and LMNA mutations could cause 
similar diseases. However, since the mutated proteins are both widely expressed and 
functions of the NE were thought to be similar in all cell types, it was less easy to 
explain their specific pathology in muscle diseases. 
An attractive model to account for the involvement of the NE in muscle disorders is 
the mechanical stress hypothesis - the lamina functions to maintain the structural 
integrity of the nucleus, so mutant lamins could lead to fragility in the NE (20,21). 
The high forces generated in tendons and contractile organs such as skeletal and 
cardiac muscle might damage weakened nuclei in these tissues, leading to 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               3                                        
malfunction and disease. In support of this idea, lamin A/C deficient cells have 
reduced viability in response to mechanical strain, and their nuclei are more fragile 
and less able to withstand tension and compression forces (10,22,23). This parallels in 
vitro studies indicating that lamin A forms the most stable interactions of the various 
lamin subtypes, and that differing degrees of mechanical stability may be required for 
individual cell types (24,25). 
In addition to muscular dystrophies, mutations in NE proteins are now known to 
cause a range of other diseases with distinct tissue-specific pathologies (see table 1). 
These include lipodystrophies (26,27), neuropathy (28), dermopathy (29), 
osteopoikilosis with melanorheostasis (30), dystonia (31,32) and premature ageing 
syndromes (33-35). The mechanical stress hypothesis is clearly not adequate to 
explain the pathologies in these other tissues, such as the abnormal white fat 
distribution observed in lipodystrophy patients (26,27), the bone abnormalities seen in 
Buschke-Ollendorf syndrome (30) and Greenberg skeletal dysplasia (36), or the 
deterioration of motor and sensory nerves in Charcot-Marie-Tooth disorder (28). 
Another popular disease model proposes that mutations in NE proteins might disrupt 
interactions between the NE and chromatin, leading to defects in gene regulation 
(37,38). Interphase nuclei are highly organized, with gene-poor chromosomes and 
heterochromatin associated with the nuclear periphery in most cell types investigated 
(39,40). Lamins and other NE proteins interact with chromatin modifying factors such 
as heterochromatin protein 1 and core histones (reviewed in 41), which may influence 
gene expression by maintaining a compartment of silenced DNA around the nuclear 
periphery (42-44). The disruption of peripheral heterochromatin has been reported in 
a number of NE-associated diseases, consistent with chromatin regulation being an 
important disease mechanism (45-47). 
Lamins and other NE proteins have also been shown to bind to a growing number of 
transcriptional regulators including the retinoblastoma protein (48,49), sterol response 
element binding protein (50,51) and germ cell-less (52,53). These results suggest that 
NE proteins may have a direct role in the regulation of specific genes, an idea that is 
strengthened by recent work uncovering the mis-expression of target genes 
downstream of these regulators in emerin and LMNA mutant cells (54). 
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A defective NE could therefore lead to disease by causing nuclear fragility under 
mechanical stress, by disrupting chromatin organization or transcriptional regulation, 
or by a combination of the above mechanisms. Recent work also suggests that LMNA 
mutations may disrupt the DNA damage response pathway, providing a possible 
explanation for the premature aging diseases Hutchison-Gilford Progeria syndrome 
and Atypical Werner syndrome (55). Other disease models for which there is 
currently less evidence include faults in cell differentiation pathways, defects in the 
functions of the contiguous ER (such as lipid regulation and the storage or release of 
Ca2+) or aberrant cell cycle regulation (reviewed in 56).  
 
Enter Proteomics 
None of these models could explain all the diverse tissue pathologies, as the mutated 
NE proteins are broadly expressed. Moreover, proximal mutations in LMNA cause 
distinct diseases that affect different tissues, and phenotypic variation in these 
disorders suggest that additional factors are involved that have yet to be identified 
(57-60). It was therefore considered that an improved fundamental understanding of 
NE organization might lead to a grand unifying disease hypothesis, and 
comprehensive identification of the protein complement of the NE was the first 
crucial step. 
Although twenty-nine structural components of the nuclear pore complex had been 
identified in yeast and mammals using proteomics (61,62), only around ten 
mammalian NE transmembrane proteins (NETs) were known by 2001 (63). 
Discounting those associated with the nuclear pores, these were the lamin B receptor 
(LBR), lamina-associated polypeptides (LAP1 and 2), emerin, MAN1, nurim, and 
syne / nesprin 1 and 2. Of these, LBR (36,64), emerin (11,65), MAN1 (30), and LAP2 
(66) have been linked to human disease (Table 1). 
Although many of the proteins associated with nuclear pores have a clear and defined 
function, relatively little is known about the other NE proteins. LBR exhibits sterol C-
14 reductase activity, and additionally binds to B-type lamins, DNA, histone H3/H4 
and heterochromatin protein 1 (reviewed in 41). Its sterol reductase activity is reduced 
in Greenberg skeletal dysplasia, but whether this is related to the disease mechanism 
has not been shown (36). The syne / nesprin genes have multiple splice isoforms, 
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some of which encode very large proteins (800-1000 kDa) of the ONM. Together 
with the subsequently discovered SUN proteins of the INM, these are thought to form 
a complex spanning the entire NE, thus linking the nuclear lamina to the cytoskeleton 
(see Figure 1, reviewed in 67). Most NETs (such as emerin, LAP1, LAP2, MAN1) 
have no associated enzymatic activity to date, yet have multiple binding partners that 
do act as enzymes. This has led to the suggestion that they principally serve as hubs 
for the assembly of multi-protein complexes whose functions are defined by their 
partners. For example, MAN1 appears to downregulate transforming growth factor-
β superfamily signaling by sequestering activated R-SMAD signal receptors to the 
NE (68). As this pathway is involved in bone morphogenetic protein signaling, its 
disruption by mutations in MAN1 could be the cause of the skeletal defects observed 
in Buschke-Ollendorf syndrome patients (30). Thus, identifying the full complement 
of NE proteins could highlight candidate partners with the requisite enzymatic 
activities to bear on the wide range of NE diseases.  
Following its success with the nuclear pores, proteomics was the method of choice to 
extend the list of NETs. However, one major problem needed to be surmounted: the 
continuity between the rough ER and the ONM causes biochemically isolated NEs to 
be contaminated by ER membranes, thus hindering the identification of novel NETs. 
The first proteomic analysis of the mammalian nuclear membrane used comparison 
between biochemical extractions to help identify true NE proteins, relying on the fact 
that the lamina and associated INM proteins are resistant to extraction with salt and 
non-ionic detergents, and that integral membrane proteins can be enriched by 
chaotrope extraction. 2-D gels were used to resolve the protein fractions remaining in 
separate salt, Triton X-100, and chaotrope (carbonate/urea) extractions of NE 
preparations. Protein spots were then excised from each gel, digested with protease, 
and the resulting peptides were identified by MALDI-TOF mass spectrometry. The 
authors considered that proteins identified in all three fractions would be good 
candidates for novel NETs. This comparative approach was successful in identifying 
seven of the ten NETs known at the time, two new splice isoforms of LAP2 and two 
novel integral membrane proteins (LUMA and SUN1, a homologue of C. elegans 
UNC-84A) which were shown to reside in the NE (69).  
The use of proteomics to identify new NE proteins was therefore a significant 
advance. However, identifications were not obtained for about 25% of the protein 
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spots excised from the 2-D gels in this study, raising the possibility that a number of 
NETs remained to be identified (63).  
The arrival of multi-dimensional protein identification technology (MudPIT) provided 
an opportunity to surmount this problem as it avoids 2-D gels altogether (70,71). In 
this high-throughput technique, the entire protein fraction under analysis is initially 
digested into peptides without prior electrophoretic separation. These peptides are 
then resolved by combined reverse phase and cation exchange chromatography, and 
eluted into an ion trap tandem mass spectrometer. The use of tandem mass 
spectrometry frequently allows protein identifications to be made from single peptides 
by using SEQUEST analysis against a database of protein sequences (72,73). MudPIT 
thus provides several advantages for identifying membrane proteins, which are often 
of low abundance and poorly resolved on 2-D gels (74). 
The second proteomic analysis of the NE combined MudPIT with an in silico 
subtractive approach to eliminate ER proteins and other contaminants from the 
analysis. A microsomal membrane fraction was prepared, containing fragments of 
ER, mitochondrial membranes and cytoskeletal proteins that normally contaminate 
NE preparations. Both NE and microsomal fractions were analyzed using MudPIT, 
and proteins appearing in both fractions were excluded from the final dataset. This 
approach was successful in identifying all of the thirteen previously characterized 
NETs expected, and an additional sixty-seven putative NE proteins with predicted 
transmembrane spans (75). Eight of these new NETs were initially shown to localize 
to the NE using tagged constructs, demonstrating the effectiveness of this new 
technique (75). Two more NETs were subsequently demonstrated to reside at the NE 
(76,77), and over a dozen more that have been tested in our laboratory thus far 
colocalize with NE markers (W.E. Powell, V. Lazou, N. Korfali and E.C. Schirmer, 
unpublished data).  
 
Proteomics and Disease 
The identification of so many novel NETs was unexpected and seemed to complicate 
rather than facilitate the development of a grand unifying disease hypothesis, because 
there were no common themes in their predicted functions. In fact, most of the novel 
NETs had either no similarity to known proteins or were related to protein families of 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               7                                        
unknown function. Those containing homology to known functional domains were 
quite varied in their predicted roles, that ranged from a sugar hydrolase to 
phosphatases and aminopeptidases (see supplementary table 7 in reference 75). 
Moreover, some NETs had multiple predicted functions, e.g. NET45 was annotated 
with both kinase and phosphatase-like domains and NET57 was predicted to have 
ubiquitin ligase, zinc finger and endonuclease regions. NET37 had a predicted sugar 
hydrolase function which was the only role related to a known pathway for muscle 
disease. However, the defects in glycosylation associated with a number of muscular 
dystrophies (including limb-girdle muscular dystrophy type 2I) all occur in the 
cytoplasm (78); so unless NET37 is in the ONM, this could not logically serve as the 
basis for a NE disease mechanism.  
That so many additional muscle-related NE diseases were identified rapidly after 
Emery-Dreifuss muscular dystrophy is, at least in part, due to the “guilt by 
association” approach. The logic of this approach devolves from certain 
characteristics of the NE diseases:  
i) The same NE protein can cause multiple similar diseases. For example, mutations 
in LMNA cause several muscle disorders including Emery-Dreifuss muscular 
dystrophy, limb-girdle muscular dystrophy, and multiple types of cardiomyopathy 
(79). 
ii) Multiple interacting NE proteins can also cause similar diseases or even variants 
of the same disease. For example, emerin and lamin A/C interact with one another 
(19) and both cause variants of Emery-Dreifuss muscular dystrophy (11,14,15). 
Similarly, mutations in LBR and MAN1 are associated with several bone 
disorders (30,36).  
iii) Many diseases that can be caused by mutations in a NE protein are genetically 
variable. For example, there are at least fifteen recognized types of limb-girdle 
muscular dystrophy (80) and over twenty variants of Charcot-Marie Tooth disease 
(81) that each map to different chromosome regions. For a number of these 
disease variants, a gene has yet to be determined.  
Genetic mapping frequently reaches a point where a chromosome region containing 
hundreds of genes is clearly linked to a disease. However, mapping this disease to a 
smaller chromosome region requires additional recombination events that might need 
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a new pedigree or another generation to identify genetically. To avoid this wait, clues 
in gene annotations can sometimes highlight a logical candidate within a chromosome 
region. For example, good candidates for investigation would be related proteins and 
partners in the same subcellular compartment. This approach has now been 
successfully applied to several NE diseases, as was clearly stated in the linking of 
cardiomyopathy to mutations in LMNA (82). Just as the muscle diseases related to the 
NE increased rapidly due to guilt by association, the identification of LMNA 
mutations linked with the premature ageing syndrome Hutchison-Gilford progeria led 
to the discovery of LMNA mutations associated with Atypical Werner’s Syndrome 
(35). 
In principle, this approach could be widely applied, but it requires that proteomics 
datasets describing organellar composition be merged with current mapping data from 
human geneticists. In the case of the information obtained in the NE proteome, there 
are two ways to focus on potential disease candidates. 
The first is to concentrate on a few proteins by identifying ones that are more likely to 
interact with, or be related to, those already associated with disease. Five of the novel 
NETs identified in the subtractive proteomics study are related to some of the 
previously characterized NETs (75).  
i) NET9 is likely to be derived from a duplication of the LAP1C gene; however this 
knowledge yielded little insight as, although first characterized in 1988 (83), no 
function has yet been identified for LAP1C. Nonetheless, both LAP1C and NET9 
(renamed LULL1) were recently shown to interact with torsinA (84), a protein 
that causes a form of inherited dystonia (31). This makes both proteins candidates 
for the guilt by association approach. In fact, torsinA itself could have been 
identified in this manner because it was present in the liver NE dataset. However, 
it was subtracted from the final results because it also appeared in microsomal 
membranes. Subsequently, torsinA was confirmed to reside in both the NE and 
ER (85), and shown to cause the disease early-onset torsion dystonia by 
accumulating in the NE of neuronal cells (84). This highlights a limitation of the 
subtractive approach - it disregards proteins that occur in multiple cellular 
locations.  
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ii) NET47 has similarity to LBR, mutations in which are responsible for Greenberg 
skeletal dysplasia (36) and the Pelger-Huet anomaly syndrome (64). The 
relationship to a protein already linked to NE disease makes this a reasonable 
candidate for the guilt by association method.  
iii) NET25 and NET66 both contain LEM domains. LAP2, Emerin, and MAN1, from 
which the LEM domain obtains its name (86), are all directly linked to disease 
(11,30,36,64-66). The NETs carrying LEM domains are therefore good candidates 
for guilt by association, because LEM domain proteins have been shown to 
interact with one another and all thus far tested have been shown to bind to 
lamins, including NET25, now renamed LEM2 (76,87).  
iv) NET53 harbors spectrin repeats and has some similarity to the syne/ nesprin 
family, although it is clearly distinct from syne/ nesprin 1 or 2. This family of 
proteins is involved in nuclear positioning in muscle syncitia in C. elegans and 
under the neuromuscular junction in mice (3,88). NET53 has subsequently been 
named nesprin 3, and appears to link the cytoskeleton to the NE via plectin (77). 
Thus, it could be involved in structural aspects of muscle and important in muscle 
diseases. 
The second way to highlight potential disease candidates is a high throughput analysis 
of the entire dataset. This was attempted by determining the genomic position of all 
the NETs identified in the liver proteomics dataset. These were then compared to 
large chromosomal regions linked to muscular dystrophies, dystonias and 
neuropathies for which a causative gene was not yet identified. This information was 
taken from multiple databases in which researchers had entered their results (75). The 
percentage of the genome over which all these linked diseases were mapped was 
calculated, and the proportion of NETs that occurred in these chromosome regions 
was determined. The incidence of NETs occurring within large chromosomal regions 
linked to these diseases was roughly twice the frequency expected for random genes 
(i.e. the percentage of the genome covered by these linked regions). This does not 
clearly link any of these NETs to the diseases: it merely indicates that within the set 
of NETs there is a greater than random chance that some will be linked to the diseases 
(75). A flaw with the initial analysis was that it relied solely on the accuracy of the 
databases, and it was subsequently discovered that several of the diseases listed in 
these databases had recently been linked to other genes but not yet updated in the 
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database. It is for this reason that the effective application of this method requires 
close interaction with expert human geneticists, who are aware of the latest 
developments in their field. Nonetheless, re-analysis of the data after removing the 
recently mapped diseases yielded an even stronger association between the NE and 
the remaining diseases. This was particularly interesting as some of the diseases were 
variants of disorders already linked to the NE (e.g. limb-girdle muscular dystrophy 
and Charcot-Marie Tooth disease). 
 
Tissue-Specificity of NETs 
Further analysis of the NE proteomics datasets has refined our hypothesis because 
there appears to be considerable variation in the composition of the NE among 
different cell types. One of the first clues that the NE might change in different tissues 
came from the observation that lamin subtypes vary in their expression patterns. The 
A-type lamins are not present in early embryos or stem cells, but are expressed in 
most differentiated cells (89-91). Moreover, the relative levels of A-type lamins and 
of the other principal lamin subtypes B1 and B2 vary in distinctive patterns among 
different cell types (92,93). The other clue was the discovery a few years before the 
subtractive proteomic study of the NET UNCL, which had varying expression levels 
in different tissues. As no UNCL mRNA was detected in liver (94), it was no surprise 
that UNCL was absent from the liver proteomics dataset (75).  
To gain further insight into this question, advantage was taken of a high throughput 
“transcriptome” dataset generated at the Genome Foundation of the Novartis 
Research Institute. Transcript levels of mRNAs obtained from 72 human and 61 
mouse tissues were compared using DNA arrays (95). This database contains 
expression information for most of the novel putative NETs identified in the 
subtractive liver NE proteomics study, and provides a numerical comparison of 
relative expression levels in different tissues. The ratios obtained by dividing the 
highest expression level by the lowest across this range of tissues were extremely high 
for the new NETs, with most exhibiting greater than a ten-fold difference between 
tissues (96,97). Nearly 20% of the putative NETs exhibited variation greater than 50-
fold, with the highest ratio at just over 300-fold. This degree of variation was 
surprising in a subcellular compartment that most had viewed previously as being 
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highly conserved in different tissues. Moreover, some of those NETs with particularly 
high degrees of variation exhibited background levels of expression in certain cell 
types.  
This high degree of variation indicated that some of the NETs might be viewed as 
being tissue-specific. Strikingly, the largest clustering of these NETs with preferential 
tissue expression patterns tended to be from cell types represented in liver (97), the 
material used to purify nuclear membranes for the subtractive proteomic study. The 
indication that several of these NETs were expressed in specific cell types provides an 
explanation for the far greater number of NETs identified in the subtractive MudPIT 
proteomics study compared to the earlier comparative MALDI-TOF analysis. In the 
earlier study, only one cell type was represented because NEs for analysis were 
purified from a cultured murine neuroblastoma cell line (69). In contrast, the rodent 
liver used in the subtractive study contained hepatocytes, Kupffer cells, lipocytes, 
endothelial cells, blood cells (contributed by the extensive vasculature, as the tissue 
was not perfused) and other cell types (75). Therefore, if each cell type in liver 
contributed a set of unique NETs, it could account in part for the discrepancy between 
the two studies in the number of NETs identified. For example, if seven unique NETs 
were identified from each of six major cell types found in liver, then over half of the 
total of eighty NETs identified in the subtractive MudPIT study would be unique to 
individual cell types (Figure 2). 
 
Tissue-Specific Partner Model for NE Diseases 
This emerging view of the NE proteome lends itself to a new model to account for the 
variation in NE disease phenotypes. The tissue specificity of NE diseases could be 
explained with the hypothesis that the widely expressed proteins underlying them 
have altered interactions with factors that are restricted to the affected tissues. Thus, a 
particular mutation in LMNA causing cardiomyopathy could disrupt an interaction 
with a tissue-specific partner in cardiac muscle, while failing to disrupt an adipocyte-
specific complex that binds at the same general site because of slight differences in 
the critical residues for binding each partner (Figure 3). Conversely, a second 
mutation in the same general binding site could selectively disrupt the adipocyte 
complex causing lipodystrophy, and a third mutation might disrupt both complexes 
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causing a multi-variant disease (such as Hutchison-Gilford progeria or Seip 
syndrome). Such partner proteins could be NETs or soluble factors with many 
potential functions, providing a possible link between this model and the gene 
expression and mechanical stability hypotheses.  
Candidates for soluble partners were also identified in the MudPIT dataset from the 
subtractive study, as many are tightly bound to lamins and NETs. Indeed, a number of 
nucleoplasmic proteins that are known to interact with lamins and other NETs were 
also present in this dataset (97): among these was the transcriptional regulator germ 
cell-less, which (as its name suggests) is preferentially expressed in the testis and 
regenerating cells (52). Other transcriptional regulators and chromatin-binding 
proteins found in this dataset may also partner with NETs to confer specific activities 
at the NE.  
The principle of tissue-specific protein complexes at the NE among NETs is 
phylogenetically conserved. In C. elegans, the NET UNC-83 is required for nuclear 
migration and is dependent upon an interaction with the NET UNC-84 for its 
targeting to the NE (98). Although UNC-84 is ubiquitously expressed, UNC-83 is 
only found in tissues where nuclear migration occurs. However, mutations in either 
unc-83 or unc-84 yield the same phenotype. The idea that altered interactions with 
partner proteins are likely to be important for NE diseases is further supported by a 
recent structural study indicating that most mutations in lamin A map to the protein 
surface (99). These disease mutations are therefore more likely to disturb the binding 
of lamin A to other proteins than to destabilize the lamin protein itself. Support for 
this model also comes from the large number of binding partners that have been 
identified for emerin, which cover the entire length of the protein (100). Moreover, 
six different monoclonal antibodies against emerin fail to recognize the protein in 
spleen cells, though each can detect it in other cell types and emerin is clearly present 
in spleen as shown by Western analysis (101). This indicates that in some cell types 
nearly the entire surface of emerin is masked by binding to other proteins.  
In addition to variation in the complement and levels of proteins present in the NE 
between cell types, there may also be variation in the post-translational modifications 
that these proteins carry. For example, a ubiquitously expressed NE protein could be 
modified in one cell type by a serine phosphorylation that blocks an interaction with a 
transcriptional repressor, while in another cell type the absence of this modification 
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could enable the interaction. It has long been known that changes in the 
phosphorylation state of lamins drive the disassembly and reassembly of the lamin 
polymer in mitosis (102-106), but much less has been done to investigate interphase 
phosphorylation. It is certain that lamins are phosphorylated throughout interphase 
(107), but it is not clear whether this directs localized disassembly for nuclear growth 
or if it regulates interactions with other proteins. In contrast, NET modification is 
clearly important for regulating protein interactions: LBR phosphorylation has been 
shown to regulate its binding to chromatin (108) and phosphorylation of emerin 
disrupts its interaction with barrier-to-autointegration factor (109). Moreover, emerin 
exhibits at least four different patterns of phosphorylation through the cell cycle and 
these are altered in Emery-Dreifuss muscular dystrophy patients (110). The 
application of the power of mass spectrometry to post-translational modifications at 
the NE in different cell types will likely lead the way to discovering how NET 
interactions are regulated. New NE proteomics datasets from our laboratory are 
consistent with such tissue variation in protein modifications (E. A. L. Fairley, N. 
Korfali, S. K. Swanson, L. Florens, and E. C. Schirmer, unpublished data).  
 
Conclusions 
In addition to the specifics discussed above, this approach merging proteomics with 
guilt by association could be adapted in many ways to identify further disease alleles. 
In cases where a complex rather than an organelle has been associated with a 
particular disorder, this approach could be used to identify the components of 
multiprotein complexes. For example, partners of emerin could be co-
immunoprecipitated from different tissues to compare complexes in those tissues 
where emerin is linked to disease with those tissues where it is not. A related 
proteomic approach that could be taken to speed identification of new disease 
candidate genes would be to compare the organellar proteome or multiprotein 
complex from control and patient cells. In cases where an organelle or complex had 
been associated with a particular disorder, this might highlight differences that could 
identify the causative gene. The principle limitation of this approach is access to the 
appropriate patient material, e.g. to avoid measuring quaternary effects tissue samples 
would ideally include a time course of disease progression from a carrier in a pedigree 
starting before presentation of clinical symptoms. Despite these difficulties, the 
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increasing sensitivity of proteomic methods will likely make this kind of approach 
viable in the near future.  
This fusion of proteomics, the guilt by association approach and the tissue-specific 
partner disease model has important implications for future proteomic studies. The 
similarity of the lipocyte cells in liver to adipocytes has highlighted a group of NETs 
specific to fat cells (97) that are candidates for guilt by association in other inherited 
lipodystrophies (111-114). The liver dataset could also be important for hepatic 
diseases. However, the MudPIT results from liver may not be the most appropriate 
dataset for identifying NETs involved in disorders of most other tissues. Clearly, it 
will now be necessary to analyze the NE proteome from further organs and cell types, 
such as muscle or nerves, in order to identify new disease candidates.  
The future benefit of such approaches will rely heavily on the interaction of human 
geneticists with proteomics laboratories. To facilitate such interactions, online 
databases could be set up to share organellar proteome data and to organize this 
according to the tissues analyzed — essentially a map of subcellular protein 
localizations throughout an organism. Between the frequent divergence to additional 
linkages uncovered during genetic mapping studies and the many currently unmapped 
or partially mapped inherited disorders, there are a great many diseases yet to be 
linked to a specific gene. Now is the perfect time to apply the powerful tool of 
organellar proteomics with the “guilt by association” approach to speed the 
identification of disease genes.  
 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               15                                        
References 
1. Gruenbaum, Y., Margalit, A., Goldman, R. D., et al. (2005) The nuclear lamina comes of age. 
Nat Rev Mol Cell Biol 6(1), 21-31 
2. Hetzer, M. W., Walther, T. C., and Mattaj, I. W. (2005) Pushing the envelope: structure, 
function, and dynamics of the nuclear periphery. Annu Rev Cell Dev Biol 21, 347-380 
3. Starr, D. A., and Han, M. (2002) Role of ANC-1 in tethering nuclei to the actin cytoskeleton. 
Science 298(5592), 406-409 
4. Crisp, M., Liu, Q., Roux, K., et al. (2006) Coupling of the nucleus and cytoplasm: role of the 
LINC complex. J Cell Biol 172(1), 41-53 
5. Fahrenkrog, B., and Aebi, U. (2003) The nuclear pore complex: nucleocytoplasmic transport 
and beyond. Nat Rev Mol Cell Biol 4(10), 757-766 
6. Stuurman, N., Heins, S., and Aebi, U. (1998) Nuclear lamins: their structure, assembly, and 
interactions. J Struct Biol 122(1-2), 42-66 
7. Worman, H. J., and Courvalin, J. C. (2005) Nuclear envelope, nuclear lamina, and inherited 
disease. Int Rev Cytol 246, 231-279 
8. Liu, J., Ben-Shahar, T., Riemer, D., et al. (2000) Essential roles for Caenorhabditis elegans 
lamin gene in nuclear organization, cell cycle progression, and spatial organization of nuclear 
pore complexes. Mol Biol Cell 11(11), 3937-3947 
9. Schirmer, E. C., Guan, T., and Gerace, L. (2001) Involvement of the lamin rod domain in 
heterotypic lamin interactions important for nuclear organization. J Cell Biol 153(3), 479-489. 
10. Lammerding, J., Schulze, P., Takahashi, T., et al. (2004) Lamin A/C deficiency causes 
defective nuclear mechanics and mechanotransduction. J Clin Invest. 113(3), 370-378 
11. Bione, S., Maestrini, E., Rivella, S., et al. (1994) Identification of a novel X-linked gene 
responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 8(4), 323-327 
12. Nagano, A., Koga, R., Ogawa, M., et al. (1996) Emerin deficiency at the nuclear membrane in 
patients with Emery- Dreifuss muscular dystrophy. Nat Genet 12(3), 254-259 
13. Manilal, S., Nguyen, T. M., Sewry, C. A., et al. (1996) The Emery-Dreifuss muscular 
dystrophy protein, emerin, is a nuclear membrane protein. Hum Mol Genet 5(6), 801-808 
14. Bonne, G., Di Barletta, M. R., Varnous, S., et al. (1999) Mutations in the gene encoding lamin 
A/C cause autosomal dominant Emery- Dreifuss muscular dystrophy. Nat Genet 21(3), 285-
288 
15. Raffaele Di Barletta, M., Ricci, E., Galluzzi, G., et al. (2000) Different Mutations in the 
LMNA Gene Cause Autosomal Dominant and Autosomal Recessive Emery-Dreifuss 
Muscular Dystrophy. Am J Hum Genet 66(4), 1407-1412 
16. Muchir, A., Bonne, G., van der Kooi, A. J., et al. (2000) Identification of mutations in the 
gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with 
atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 9(9), 1453-1459 
17. Fatkin, D., MacRae, C., Sasaki, T., et al. (1999) Missense mutations in the rod domain of the 
lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease [see 
comments]. N Engl J Med 341(23), 1715-1724 
18. Ostlund, C., Bonne, G., Schwartz, K., et al. (2001) Properties of lamin A mutants found in 
Emery-Dreifuss muscular dystrophy, cardiomyopathy and Dunnigan-type partial 
lipodystrophy. J Cell Sci 114( 24), 4435-4445 
19. Clements, L., Manilal, S., Love, D. R., et al. (2000) Direct interaction between emerin and 
lamin A. Biochem Biophys Res Commun 267(3), 709-714 
20. Fidzianska, A., Toniolo, D., and Hausmanowa-Petrusewicz, I. (1998) Ultrastructural 
abnormality of sarcolemmal nuclei in Emery-Dreifuss muscular dystrophy (EDMD). J Neurol 
Sci 159(1), 88-93 
21. Sullivan, T., Escalante-Alcalde, D., Bhatt, H., et al. (1999) Loss of A-type lamin expression 
compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 147(5), 
913-920 
22. Broers, J. L., Peeters, E. A., Kuijpers, H. J., et al. (2004) Decreased mechanical stiffness in 
LMNA-/- cells is caused by defective nucleo-cytoskeletal integrity: implications for the 
development of laminopathies. Hum Mol Genet 13(21), 2567-2580 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               16                                        
23. Lammerding, J., Hsiao, J., Schulze, P. C., et al. (2005) Abnormal nuclear shape and impaired 
mechanotransduction in emerin-deficient cells. J Cell Biol 170(5), 781-791 
24. Georgatos, S. D., Stournaras, C., and Blobel, G. (1988) Heterotypic and homotypic 
associations between the nuclear lamins: site- specificity and control by phosphorylation. Proc 
Natl Acad Sci U S A 85(12), 4325-4329 
25. Schirmer, E. C., and Gerace, L. (2004) The stability of the nuclear lamina polymer changes 
with the composition of lamin subtypes according to their individual binding strengths. J Biol 
Chem  
26. Cao, H., and Hegele, R. A. (2000) Nuclear lamin A/C R482Q mutation in Canadian kindreds 
with Dunnigan- type familial partial lipodystrophy. Hum Mol Genet 9(1), 109-112 
27. Shackleton, S., Lloyd, D. J., Jackson, S. N., et al. (2000) LMNA, encoding lamin A/C, is 
mutated in partial lipodystrophy. Nat Genet 24(2), 153-156 
28. De Sandre-Giovannoli, A., Chaouch, M., Kozlov, S., et al. (2002) Homozygous defects in 
LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal 
neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 
70(3), 726-736 
29. Navarro, C. L., De Sandre-Giovannoli, A., Bernard, R., et al. (2004) Lamin A and 
ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive 
dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 13(20), 2493-2503 
30. Hellemans, J., Preobrazhenska, O., Willaert, A., et al. (2004) Loss-of-function mutations in 
LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat 
Genet 36(11), 1213-1218 
31. Ozelius, L. J., Hewett, J. W., Page, C. E., et al. (1997) The early-onset torsion dystonia gene 
(DYT1) encodes an ATP-binding protein. Nat Genet 17(1), 40-48 
32. Naismith, T. V., Heuser, J. E., Breakefield, X. O., et al. (2004) TorsinA in the nuclear 
envelope. Proc Natl Acad Sci U S A 101(20), 7612-7617 
33. De Sandre-Giovannoli, A., Bernard, R., Cau, P., et al. (2003) Lamin A Truncation in 
Hutchinson-Gilford Progeria. Science 300(5628), 2055 
34. Eriksson, M., Brown, W. T., Gordon, L. B., et al. (2003) Recurrent de novo point mutations in 
lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423(6937), 293-298 
35. Chen, L., Lee, L., Kudlow, B. A., et al. (2003) LMNA mutations in atypical Werner's 
syndrome. Lancet 362(9382), 440-445 
36. Waterham, H., Koster, J., Mooyer, P., et al. (2003) Autosomal Recessive HEM/Greenberg 
Skeletal Dysplasia Is Caused by 3beta-Hydroxysterol Delta14-Reductase Deficiency Due to 
Mutations in the Lamin B Receptor Gene. Am J Hum Genet 72(4), 1013-1017 
37. Ostlund, C., Ellenberg, J., Hallberg, E., et al. (1999) Intracellular trafficking of emerin, the 
Emery-Dreifuss muscular dystrophy protein. J Cell Sci 112, 1709-1719 
38. Cohen, M., Lee, K. K., Wilson, K. L., et al. (2001) Transcriptional repression, apoptosis, 
human disease and the functional evolution of the nuclear lamina. Trends Biochem Sci 26(1), 
41-47 
39. Qumsiyeh, M. B. (1999) Structure and function of the nucleus: anatomy and physiology of 
chromatin. Cell Mol Life Sci 55(8-9), 1129-1140 
40. Gilbert, N., Gilchrist, S., and Bickmore, W. A. (2005) Chromatin organization in the 
mammalian nucleus. Int Rev Cytol 242, 283-336 
41. Mattout-Drubezki, A., and Gruenbaum, Y. (2003) Dynamic interactions of nuclear lamina 
proteins with chromatin and transcriptional machinery. Cell Mol Life Sci 60(10), 2053-2063 
42. Andrulis, E. D., Neiman, A. M., Zappulla, D. C., et al. (1998) Perinuclear localization of 
chromatin facilitates transcriptional silencing. Nature 394(6693), 592-595 
43. Zink, D., Bornfleth, H., Visser, A., et al. (1999) Organization of early and late replicating 
DNA in human chromosome territories. Exp Cell Res 247(1), 176-188 
44. Tumbar, T., Sudlow, G., and Belmont, A. S. (1999) Large-scale chromatin unfolding and 
remodeling induced by VP16 acidic activation domain. J Cell Biol 145(7), 1341-1354 
45. Maraldi, N. M., Squarzoni, S., Sabatelli, P., et al. (2002) Emery-Dreifuss muscular dystrophy, 
nuclear cell signaling and chromatin remodeling. Adv Enzyme Regul 42, 1-18 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               17                                        
46. Goldman, R. D., Shumaker, D. K., Erdos, M. R., et al. (2004) Accumulation of mutant lamin 
A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria 
syndrome. Proc Natl Acad Sci U S A 101(24), 8963-8968 
47. Filesi, I., Gullotta, F., Lattanzi, G., et al. (2005) Alterations of nuclear envelope and chromatin 
organization in mandibuloacral dysplasia, a rare form of laminopathy. Physiol Genomics 
23(2), 150-158 
48. Mancini, M. A., Shan, B., Nickerson, J. A., et al. (1994) The retinoblastoma gene product is a 
cell cycle-dependent, nuclear matrix-associated protein. Proc Natl Acad Sci U S A 91(1), 418-
422 
49. Markiewicz, E., Dechat, T., Foisner, R., et al. (2002) Lamin A/C binding protein LAP2alpha 
is required for nuclear anchorage of retinoblastoma protein. Mol Biol Cell 13(12), 4401-4413 
50. Lloyd, D. J., Trembath, R. C., and Shackleton, S. (2002) A novel interaction between lamin A 
and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet 
11(7), 769-777 
51. Capanni, C., Mattioli, E., Columbaro, M., et al. (2005) Altered pre-lamin A processing is a 
common mechanism leading to lipodystrophy. Hum Mol Genet 14(11), 1489-1502 
52. Nili, E., Cojocaru, G. S., Kalma, Y., et al. (2001) Nuclear membrane protein LAP2beta 
mediates transcriptional repression alone and together with its binding partner GCL (germ-
cell-less). J Cell Sci 114(18), 3297-3307 
53. Holaska, J. M., Lee, K., Kowalski, A. K., et al. (2003) Transcriptional repressor germ cell-less 
(GCL) and barrier to autointegration factor (BAF) compete for binding to emerin in vitro. J 
Biol Chem 278(9), 6969-6975 
54. Bakay, M., Wang, Z., Melcon, G., et al. (2006) Nuclear envelope dystrophies show a 
transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle 
regeneration. Brain 129(4), 996-1013 
55. Liu, B., Wang, J., Chan, K. M., et al. (2005) Genomic instability in laminopathy-based 
premature aging. Nat Med 11(7), 780-785 
56. Somech, R., Shaklai, S., Amariglio, N., et al. (2005) Nuclear envelopathies--raising the 
nuclear veil. Pediatr Res 57(5 Pt 2), 8R-15R 
57. Mercuri, E., Poppe, M., Quinlivan, R., et al. (2004) Extreme variability of phenotype in 
patients with an identical missense mutation in the lamin A/C gene: from congenital onset 
with severe phenotype to milder classic Emery-Dreifuss variant. Arch Neurol 61(5), 690-694 
58. Mercuri, E., Brown, S. C., Nihoyannopoulos, P., et al. (2005) Extreme variability of skeletal 
and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. 
Muscle Nerve 31(5), 602-609 
59. Tazir, M., Azzedine, H., Assami, S., et al. (2004) Phenotypic variability in autosomal 
recessive axonal Charcot-Marie-Tooth disease due to the R298C mutation in lamin A/C. 
Brain 127(1), 154-163 
60. Benedetti, S., Bertini, E., Iannaccone, S., et al. (2005) Dominant LMNA mutations can cause 
combined muscular dystrophy and peripheral neuropathy. J Neurol Neurosurg Psychiatry 
76(7), 1019-1021 
61. Rout, M. P., Aitchison, J. D., Suprapto, A., et al. (2000) The yeast nuclear pore complex: 
composition, architecture, and transport mechanism. J Cell Biol 148(4), 635-651. 
62. Cronshaw, J., Krutchinsky, A., Zhang, W., et al. (2002) Proteomic analysis of the mammalian 
nuclear pore complex. J Cell Biol 158(5), 915-927 
63. Schirmer, E., and Gerace, L. (2002) Organellar proteomics: the prizes and pitfalls of opening 
the nuclear envelope. Genome Biol 3(4), reviews1008.1001-1008.1004 
64. Hoffmann, K., Dreger, C., Olins, A., et al. (2002) Mutations in the gene encoding the lamin B 
receptor produce an altered nuclear morphology in granulocytes (Pelger-Huet anomaly). Nat 
Genet 31(4), 410-414 
65. Paulin-Levasseur, M., Blake, D. L., Julien, M., et al. (1996) The MAN antigens are non-lamin 
constituents of the nuclear lamina in vertebrate cells. Chromosoma 104(5), 367-379 
66. Taylor, M. R., Slavov, D., Gajewski, A., et al. (2005) Thymopoietin (lamina-associated 
polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat 26(6), 566-
574 
67. Worman, H. J., and Gundersen, G. G. (2006) Here come the SUNs: a nucleocytoskeletal 
missing link. Trends Cell Biol 16(2), 67-69 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               18                                        
68. Pan, D., Estevez-Salmeron, L. D., Stroschein, S. L., et al. (2005) The integral inner nuclear 
membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling 
by the transforming growth factor-{beta} superfamily of cytokines. J Biol Chem 280(16), 
15992-16001 
69. Dreger, M., Bengtsson, L., Schoneberg, T., et al. (2001) Nuclear envelope proteomics: novel 
integral membrane proteins of the inner nuclear membrane. Proc Natl Acad Sci U S A 98(21), 
11943-11948. 
70. Washburn, M. P., Wolters, D., and Yates, J. R. r. (2001) Large-scale analysis of the yeast 
proteome by multidimensional protein identification technology. Nat Biotechnol 19(3), 242-
247 
71. Wolters, D. A., Washburn, M. P., and Yates, J. R. r. (2001) An automated multidimensional 
protein identification technology for shotgun proteomics. Anal Chem 73(23), 5683-5690 
72. Eng, J., McCormack, A., and Yates, J. r. (1994) An Approach to Correlate Tandem Mass 
Spectral Data of Peptides with Amino Acid Sequences in a Protein Database. J Am Soc Mass 
Spectrom 5, 976-989 
73. Ducret, A., Van Oostveen, I., Eng, J. K., et al. (1998) High throughput protein 
characterization by automated reverse-phase chromatography/electrospray tandem mass 
spectrometry. Protein Sci 7(3), 706-719 
74. Santoni, V., Molloy, M., and Rabilloud, T. (2000) Membrane proteins and proteomics: un 
amour impossible? Electrophoresis 21(6), 1054-1070 
75. Schirmer, E. C., Florens, L., Guan, T., et al. (2003) Nuclear membrane proteins with potential 
disease links found by subtractive proteomics. Science 301(5638), 1380-1382 
76. Brachner, A., Reipert, S., Foisner, R., et al. (2005) LEM2 is a novel MAN1-related inner 
nuclear membrane protein associated with A-type lamins. J Cell Sci 118(24), 5797-5810 
77. Wilhelmsen, K., Litjens, S. H., Kuikman, I., et al. (2005) Nesprin-3, a novel outer nuclear 
membrane protein, associates with the cytoskeletal linker protein plectin. J Cell Biol 171(5), 
799-810 
78. Brockington, M., Yuva, Y., Prandini, P., et al. (2001) Mutations in the fukutin-related protein 
gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of 
congenital muscular dystrophy MDC1C. Hum Mol Genet 10(25), 2851-2859 
79. Broers, J. L., Hutchison, C. J., and Ramaekers, F. C. (2004) Laminopathies. J Pathol 204(4), 
478-488 
80. Emery, A. E. (2002) The muscular dystrophies. Lancet 359(9307), 687-695 
81. Shy, M. E. (2004) Charcot-Marie-Tooth disease: an update. Curr Opin Neurol 17(5), 579-585 
82. Brodsky, G. L., Muntoni, F., Miocic, S., et al. (2000) Lamin A/C gene mutation associated 
with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 101(5), 
473-476 
83. Senior, A., and Gerace, L. (1988) Integral membrane proteins specific to the inner nuclear 
membrane and associated with the nuclear lamina. J Cell Biol 107(6), 2029-2036 
84. Goodchild, R. E., Kim, C. E., and Dauer, W. T. (2005) Loss of the dystonia-associated protein 
torsinA selectively disrupts the neuronal nuclear envelope. Neuron 48(6), 923-932 
85. Goodchild, R. E., and Dauer, W. T. (2004) Mislocalization to the nuclear envelope: an effect 
of the dystonia-causing torsinA mutation. Proc Natl Acad Sci U S A 101(3), 847-852 
86. Lin, F., Blake, D. L., Callebaut, I., et al. (2000) MAN1, an inner nuclear membrane protein 
that shares the LEM domain with lamina-associated polypeptide 2 and emerin. J Biol Chem 
275(7), 4840-4847 
87. Lee, K. K., and Wilson, K. L. (2004) All in the family: evidence for four new LEM-domain 
proteins Lem2 (NET-25), Lem3, Lem4 and Lem5 in the human genome. Symp Soc Exp Biol 
(56), 329-339 
88. Grady, R. M., Starr, D. A., Ackerman, G. L., et al. (2005) From the Cover: Syne proteins 
anchor muscle nuclei at the neuromuscular junction. Proc Natl Acad Sci U S A 102(12), 4359-
4364 
89. Houliston, E., Guilly, M. N., Courvalin, J. C., et al. (1988) Expression of nuclear lamins 
during mouse preimplantation development. Development 102(2), 271-278 
90. Lehner, C. F., Stick, R., Eppenberger, H. M., et al. (1987) Differential expression of nuclear 
lamin proteins during chicken development. J Cell Biol 105(1), 577-587 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               19                                        
91. Rober, R. A., Gieseler, R. K., Peters, J. H., et al. (1990) Induction of nuclear lamins A/C in 
macrophages in in vitro cultures of rat bone marrow precursor cells and human blood 
monocytes, and in macrophages elicited in vivo by thioglycollate stimulation. Exp Cell Res 
190(2), 185-194 
92. Broers, J. L., Machiels, B. M., Kuijpers, H. J., et al. (1997) A- and B-type lamins are 
differentially expressed in normal human tissues. Histochem Cell Biol 107(6), 505-517 
93. Jansen, M., Machiels, B., Hopman, A., et al. (1997) Comparison of A and B-type lamin 
expression in reactive lymph nodes and nodular sclerosing Hodgkin's disease. Histopathology 
31(4), 304-312 
94. Fitzgerald, J., Kennedy, D., Viseshakul, N., et al. (2000) UNCL, the mammalian homologue 
of UNC-50, is an inner nuclear membrane RNA-binding protein. Brain Res 877(1), 110-123 
95. Su, A. I., Cooke, M. P., Ching, K. A., et al. (2002) Large-scale analysis of the human and 
mouse transcriptomes. Proc Natl Acad Sci U S A 99(7), 4465-4470 
96. Schirmer, E. C., Florens, L., Guan, T., et al. (2005) Identification of novel integral membrane 
proteins of the nuclear envelope with potential disease links using subtractive proteomics. In: 
Chadwick, D. J., and Goode, J. A. (eds) pp 63-76. Novartis Found Symp No. 264 Nuclear 
Organization in Development and Disease, John Wiley & Sons Ltd., Chichester and New 
York 
97. Schirmer, E. C., and Gerace, L. (2005) The nuclear membrane proteome: extending the 
envelope. Trends Biochem Sci 30(10), 551-558 
98. Starr, D. A., Hermann, G. J., Malone, C. J., et al. (2001) unc-83 encodes a novel component 
of the nuclear envelope and is essential for proper nuclear migration. Development 128(24), 
5039-5050. 
99. Strelkov, S. V., Schumacher, J., Burkhard, P., et al. (2004) Crystal Structure of the Human 
Lamin A Coil 2B Dimer: Implications for the Head-to-tail Association of Nuclear Lamins. J 
Mol Biol 343(4), 1067-1080 
100. Bengtsson, L., and Wilson, K. L. (2004) Multiple and surprising new functions for emerin, a 
nuclear membrane protein. Curr Opin Cell Biol 16(1), 73-79 
101. Tunnah, D., Sewry, C. A., Vaux, D., et al. (2005) The apparent absence of lamin B1 and 
emerin in many tissue nuclei is due to epitope masking. J Mol Histol 36(5), 337-344 
102. Ottaviano, Y., and Gerace, L. (1985) Phosphorylation of the nuclear lamins during interphase 
and mitosis. J Biol Chem 260(1), 624-632 
103. Dessev, G., Iovcheva-Dessev, C., Bischoff, J. R., et al. (1991) A complex containing p34cdc2 
and cyclin B phosphorylates the nuclear lamin and disassembles nuclei of clam oocytes in 
vitro. J Cell Biol 112(4), 523-533 
104. Ward, G. E., and Kirschner, M. W. (1990) Identification of cell cycle-regulated 
phosphorylation sites on nuclear lamin C. Cell 61(4), 561-577 
105. Peter, M., Heitlinger, E., Haner, M., et al. (1991) Disassembly of in vitro formed lamin head-
to-tail polymers by CDC2 kinase. Embo J 10(6), 1535-1544 
106. Heald, R., and McKeon, F. (1990) Mutations of phosphorylation sites in lamin A that prevent 
nuclear lamina disassembly in mitosis. Cell 61(4), 579-589 
107. Kill, I. R., and Hutchison, C. J. (1995) S-phase phosphorylation of lamin B2. FEBS Lett 
377(1), 26-30 
108. Takano, M., Takeuchi, M., Ito, H., et al. (2002) The binding of lamin B receptor to chromatin 
is regulated by phosphorylation in the RS region. Eur J Biochem 269(3), 943-953 
109. Hirano, Y., Segawa, M., Ouchi, F. S., et al. (2005) Dissociation of emerin from barrier-to-
autointegration factor is regulated through mitotic phosphorylation of emerin in a xenopus egg 
cell-free system. J Biol Chem 280(48), 39925-39933 
110. Ellis, J. A., Craxton, M., Yates, J. R., et al. (1998) Aberrant intracellular targeting and cell 
cycle-dependent phosphorylation of emerin contribute to the Emery-Dreifuss muscular 
dystrophy phenotype. J Cell Sci 111 (6), 781-792 
111. Pivnick, E. K., Angle, B., Kaufman, R. A., et al. (2000) Neonatal progeroid (Wiedemann-
Rautenstrauch) syndrome: report of five new cases and review. Am J Med Genet 90(2), 131-
140 
112. Ferrarini, A., Milani, D., Bottigelli, M., et al. (2004) Two new cases of Barraquer-Simons 
syndrome. Am J Med Genet A 126(4), 427-429 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               20                                        
113. Berger, J. R., Oral, E. A., and Taylor, S. I. (2002) Familial lipodystrophy associated with 
neurodegeneration and congenital cataracts. Neurology 58(1), 43-47 
114. Rajab, A., Khaburi, M., Spranger, S., et al. (2003) Congenital generalized lipodystrophy, 
mental retardation, deafness, short stature, and slender bones: a newly recognized syndrome? 
Am J Med Genet A 121(3), 271-276 
115. Csoka, A. B., Cao, H., Sammak, P. J., et al. (2004) Novel lamin A/C gene (LMNA) mutations 
in atypical progeroid syndromes. J Med Genet 41(4), 304-308 
116. Caux, F., Dubosclard, E., Lascols, O., et al. (2003) A new clinical condition linked to a novel 
mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, 
disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin 
Endocrinol Metab 88(3), 1006-1013 
117. Novelli, G., Muchir, A., Sangiuolo, F., et al. (2002) Mandibuloacral dysplasia is caused by a 
mutation in LMNA-encoding lamin A/C. Am J Hum Genet 71(2), 426-431 
118. Agarwal, A. K., Fryns, J. P., Auchus, R. J., et al. (2003) Zinc metalloproteinase, ZMPSTE24, 
is mutated in mandibuloacral dysplasia. Hum Mol Genet 12(16), 1995-2001 
 
Guilt by Association: the Nuclear Envelope and Disease 
                                                                                                               21                                        
Figure Legends 
 
Table 1 – Inherited diseases associated with the nuclear envelope. 
OMIM – Online Mendelian Inheritance in Man database at the National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/). # - the disease is caused by mutations in the protein 
shown. * - mutations are associated with the disease but a causal link has not been conclusively 
demonstrated. AD – Autosomal Dominant. AR – Autosomal Recessive.  
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Figure 1 
 
Structure of the Nuclear Envelope. 
The nuclear envelope is composed of a double lipid bilayer punctuated with nuclear pore complexes 
(NPCs). The inner nuclear membrane (INM) harbors a unique set of integral proteins (green) with 
varying numbers of transmembrane spans. Many of these interact with the underlying nuclear lamina 
(red), a meshwork of intermediate filaments that provide strength and support to the membrane system. 
The outer nuclear membrane (ONM) and lumen are common to the endoplasmic reticulum (ER). 
Ribosomes and a shared set of integral membrane proteins (purple) are associated with the ONM and 
ER. The ONM also has some unique components that are believed to connect the cytoskeleton (blue 
filaments) to the nuclear envelope. These proteins (known as synes/nesprins) appear to be retained in 
the ONM by an interaction with INM factors (known as SUNs) that bridges the luminal space, thus 
linking the cytoskeleton to the nuclear lamina.  
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Figure 2 
 
Tissue Specificity of Nuclear Envelope Transmembrane proteins. 
Venn diagram representing a hypothetical expression pattern of nuclear envelope transmembrane 
proteins (NETs) in the liver. A central core of NETs (white) are broadly expressed, whilst others are 
restricted to specific cell types. Some of these cell types are unique to liver, but others may in essence 
occur in multiple tissues such as the lipocytes that are similar to adipocytes and fatty tissue. If each of 
the six groups of liver cells shown expressed seven unique NETs, then over half of the total of eighty 
NETs currently identified in liver would be cell-type specific. The identification of the full complement 
of NETs, including those involved in diseases of other organs, is likely to require the analysis of other 
tissue types. 
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Figure 3 
 
A Tissue-Specific Partner Model for Nuclear Envelope diseases. 
An intriguing aspect of NE disorders is that proximal mutations in lamin A lead to disease phenotypes 
in distinct tissues, despite the fact that lamin A is widely expressed. This could be explained with the 
hypothesis that mutations in ubiquitous NETs have altered interactions with factors that are restricted 
to the affected organs. For example as depicted here, two tissue-specific complexes with overlapping 
binding sites interact with wild type (WT) and mutant lamin A (represented by the red bar) in heart and 
fat cells. Mutant I causes lipodystrophy by disrupting the binding of the adipocyte-specific complex 
(blue/cyan), whilst not affecting the interaction of the cardiac complex (green/yellow) with lamin A 
due to slight differences in the residues critical for binding each partner. The proximal defect in mutant 
II selectively disrupts the interaction of lamin A with the heart-specific complex, leading to 
cardiomyopathy. Mutant III inhibits the binding of both partners causing disease in multiple tissues, as 
seen in Hutchison-Gilford progeria syndrome, Mandibuloacral dysplasia and Seip syndrome. 
 Disease Synonym Gene OMIM Inheritance Phenotype 
Emery-Dreifuss muscular 
dystrophy, type 1/2/3 
EDMD2/3 
EDMD1 
LMNA  
EMD/STA 
#181350 
#310300 
Autosomal dominant 
X-linked 
Atrophy and weakness of muscles in arms, legs, face, spine and heart. Contractures 
(stiff/fixed joints) of elbows, Achilles tendon and neck. Dilated cardiomyopathy with 
conduction abnormalities. 
Limb girdle muscular dystrophy, 
type 1B LGMD1B LMNA #159001 Autosomal dominant 
Progressive pelvic girdle weakness (shoulder & hip muscles) with later development 
of dilated cardiomyopathy with conduction abnormalities. 
Dilated Cardiomyopathy with 
conduction defect CMD1A LMNA #115200 Autosomal dominant 
Ventricular dilation and impaired cystolic function. Sudden death due to cardiac pump 
failure often occurs after conduction abnormalities. No skeletal muscles affected. 
Dunnigan-type familial partial 
lipodystrophy FPLD2 LMNA #151660 Autosomal dominant 
Loss of subcutaneous fat from limbs and trunk with simultaneous accumulation in 
face and neck. Insulin resistance and diabetes mellitus. 
Seip Syndrome BSCL2 BSCL2 LMNA 
#269700 
*150330 
Autosomal recessive 
Unknown 
Generalised lipodystrophy, adipose tissue absent from early infancy. 
Hypertriglyceridemia, hyperglycemia, diabetes mellitus, mild mental retardation, 
cardiomyopathy and Acanthosis nigricans (dark, rough skin patches). 
Lipotrophy with diabetes, hepatic 
steatosis, hypertrophic 
cardiomyopathy and 
leukomelanodermic papules 
LDHCP LMNA #608056 Unknown Generalised lipoatrophy with acute liver steatosis (fatty liver), cutaneous pigment 
manifestations and cardiac abnormalities. 
Mandibuloacral dysplasia, type A/B MADA MADB 
LMNA 
FACE1/ZMPSTE24 
#248370 
#608612 
Autosomal dominant 
Autosomal recessive 
Postnatal growth retardation, craniofacial anomalies (esp crowding or loss of teeth), 
skeletal malformations, mottled skin pigmentation, stiff joints and alopecia 
(autoimmume hair loss). Partial lipodystrophy. insulin resistance and diabetes. 
Restrictive Dermopathy RD LMNA FACE1/ZMPSTE24 
*150330 
*606480 Autosomal recessive 
Abnormally rigid and translucent skin, joint contractures and pulmonary hypoplasia. 
Impaired foetal body movements lead to deformity. Early neonatal death due to 
respiratory insufficiency. 
Charcot-Marie-Tooth disorder, type 
2B1 CMT2B1 LMNA #605588 Autosomal recessive 
Progressive deterioration of motor and sensory nerves leading to atrophy of limb 
muscles and numbness/sensory problems. Nerve conduction velocities not affected. 
Pelger-Huet anomaly PHA LBR #169400 Autosomal dominant  
Neutrophil nuclei in heterozygotes have fewer segments and course chromatin, with 
no other effects on normal health. Homozygotes are also prone to epilepsy and 
skeletal abnormalities, eg polydactyly and metacarpal shortening.  
Hydrops-ectopic calcification-moth-
eaten skeletal dysplasia. 
(Greenberg dysplasia) 
HEM/GSD LBR #215140 Autosomal recessive 
Early in utero lethality. Foetal hydrops (tissue oedema), short limbs, 
chondrodystrophy (cartilage converted to bone) and abnormal ‘moth-eaten’  
disorganised appearance of bones by X-ray. 
Buschke-Ollendorff syndrome BOS MAN1/LEMD3 #166700 Autosomal dominant 
Osteopoikilosis (multiple small ovoid areas of increased bone density) with 
melorheostosis (abnormal bone growth resembling cande wax) sometimes also 
accompanied by joint contractures, sclerodermatous skin lesions, muscle atrophy, 
hemangiomas, and lymphedema. 
Hutchison-Gilford Progeria 
syndrome HGPS LMNA #176670 
Do novo mutation/ 
Autosomal dominant 
Childhood onset of premature ageing including growth retardation, baldness, facial 
hypoplasia, delayed tooth formation, aged skin, osteoporosis, atherosclerosis, 
arthritis. Teenage mortality due to cardiovascular disease. 
Atypical Werner syndrome AWS LMNA *150330 Autosomal dominant Adult onset. Hard, tight skin, cataracts, subcutaneous calcification, premature 
arterioslcerosis, diabetes mellitus, premature ageing of face. 
Torsion Dystonia DYT1 TOR1A/DYT1 #128100 Autosomal dominant, 30-40% penetrance 
Prolonged, involuntary muscle contractions induce abnormal posture and twisting or 
repetitive movements in arms and legs. Caused by CNS dysfunction rather than 
neurodegeneration. 
Facioscapulohumeral Dystrophy FSHD D4Z4 repeats  Autosomal dominant Weakness of facial and shoulder girdle muscles, often asymmetric. Progresses downwards to upper arm muscles, limb girdle and legs. 
